Shots:
- The P-III (KEYNOTE-B15/EV-304) trial assessed Keytruda + Padcev (IV), followed by surgery & then Keytruda + Padcev vs neoadj. SoC + surgery in cisplatin-eligible MIBC pts
- Trial showed 47% reduction in the risk of tumor recurrence, progression, or death, with an estimated 79.4% pts event-free at 2yrs. vs 66.2% with SoC, plus the combination also decreased death risk by 35%
- Trial also showed a pCR rate of 55.8% vs 32.5% at the time of surgery, while EFS, OS & pCR benefits remain consistent across all pre-defined subgroups; results were presented at ASCO GU 2026 & will be discussed with global regulators for potential filings
Ref: Pfizer | Image: Pfizer, Merck & Astellas | Press Release
Related News: Merck Presents P-III (LITESPARK-022) Trial Data on Keytruda + Welireg in Clear Cell Renal Cell Carcinoma (RCC) at ASCO GU 2026
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
